title: [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
abstract: Multiple sclerosis (MS)--autoimmune disease of CNS, characterized by myelin destruction and axonal damage. The action of drugs recommended for its treatment [symbol: see text] aimy[symbol: see text] at the reduction of the autoimmune responses. These responses lead to the neurological damage. One of immunoregulators is glatiramer acetate--Copaxone. Copaxone acts at different phases of MS pathogenesis and probably has a neuroprotective action. Copaxone reduces the rate of relapses and leads to clinical stabilisation in cases of relapsing-remmiting MS. Its efficacy and safety has been confirmed in long-term clinical and MRI-trials. Copaxone has few side-effects that are non-significant.
authors.forename: T E
authors.initials: TE
authors.lastname: Shmidt
authors.forename: T D
authors.initials: TD
authors.lastname: Zhuchenko
authors.forename: N N
authors.initials: NN
authors.lastname: Iakhno
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D000068717:Glatiramer Acetate; D006801:Humans; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D019208:Brain-Derived Neurotrophic Factor; D010455:Peptides; D000068717:Glatiramer Acetate